Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:32:49.345Z.
Calculation as of: 2026-10-06T22:32:49.345Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$1.23B
EV/FCF Ratio
15.32x
TTM Avg
580.30x
3Y Avg
501.54x
5Y Avg
501.54x
Market Cap
$1.22B
EV/FCF Ratio
23.98x
TTM Avg
28.78x
3Y Avg
30.44x
5Y Avg
41.95x
Market Cap
$1.18B
EV/FCF Ratio
N/A
TTM Avg
74.41x
3Y Avg
125.98x
5Y Avg
125.98x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.24B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.23B | 50.31x | 50.12x | 50.12x | 50.12x |
| Cronos Group Inc. (CRON)vs › | $1.23B | 15.32x | 580.30x | 501.54x | 501.54x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 23.98x | 28.78x | 30.44x | 41.95x |
| Tyra Biosciences, Inc. (TYRA)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.18B | N/A | 74.41x | 125.98x | 125.98x |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
